EFFICACY OF LY2951742 IN SUBGROUPS OF PATIENTS WITH MIGRAINE OF DIFFERENT FREQUENCY

被引：0
|
作者：
Skljarevski, V. [1 ]
Martinez, J. [1 ]
Oakes, T. [1 ]
Ferguson, M. [2 ]
Tanaka, Y. [3 ]
Due, M. [4 ]
Schacht, A. [5 ]
机构：
[1] Eli Lilly & Co, Pain Team Med, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Clin Operat, Scarborough, ON, Canada
[3] Eli Lilly & Co, RWA Capabil & Datamart, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Global Sci Commun, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Elanco, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2016年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EHMTC-0111
引用
收藏
页码：42 / 43
页数：2
相关论文
共 50 条
  • [1] Efficacy of LY2951742 in subgroups of patients with migraine of different frequency
    Skljarevski, V
    Martinez, J. M.
    Oakes, T.
    Ferguson, M.
    Tanaka, Y.
    Due, M. R.
    Schacht, A. L.
    HEADACHE, 2016, 56 : 67 - 67
  • [2] Site of effect of LY2951742 for migraine prophylaxis
    Tfelt-Hansen, Peer
    LANCET NEUROLOGY, 2015, 14 (01): : 31 - 32
  • [3] Site of effect of LY2951742 for migraine prophylaxis Reply
    Dodick, David W.
    Goadsby, Peter J.
    Spierings, Egilius L. H.
    Scherer, Joel C.
    Sweeney, Steven P.
    Grayzel, David S.
    LANCET NEUROLOGY, 2015, 14 (01): : 32 - 33
  • [4] PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF LY2951742, A CALCITONIN GENE RELATED PEPTIDE ANTIBODY, IN MIGRAINE PATIENTS
    Kielbasa, W.
    Quinlan, T.
    Bell, R.
    Miller, B.
    Skljarevski, V.
    CEPHALALGIA, 2016, 36 : 25 - 25
  • [5] Pharmacokinetic and Pharmacodynamic Modeling of LY2951742, a Calcitonin Gene Related Peptide Antibody, in Migraine Patients
    Kielbasa, William
    Quinlan, Tonya
    Bell, Robert
    Millen, Bradley
    Skljarevski, Vladimir
    NEUROLOGY, 2016, 86
  • [6] Pharmacokinetic and pharmacodynamic modeling of LY2951742, a calcitonin gene related peptide antibody, in migraine patients
    Kielbasa, W.
    Quinlan, T.
    Bell, R.
    Miller, B.
    Skljarevski, V
    HEADACHE, 2016, 56 : 61 - 62
  • [7] Efficacy and safety of LY2951742 in a randomized, double-blind, placebo-controlled, dose-ranging study in patients with migraine
    Oakes, T.
    Zhang, Q.
    Ferguson, M.
    Skljarevski, V
    Martinez, J. M.
    Johnson, K. W.
    Schacht, A. L.
    Due, M. R.
    Goadsby, P.
    Dodick, D. W.
    HEADACHE, 2016, 56 : 68 - 68
  • [8] EFFICACY AND SAFETY OF LY2951742 IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY IN PATIENTS WITH MIGRAINE
    Skljarevski, V.
    Oakes, T.
    Ferguson, M.
    Zhang, Q.
    Martinez, J.
    Johnson, K.
    Schacht, A.
    Due, M.
    Goadsby, P.
    Dodick, D.
    CEPHALALGIA, 2016, 36 : 42 - 42
  • [9] Evaluation of Efficacy and Safety of LY2951742 in Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Dose-Ranging Studies in Patients With Migraine
    Iyengar, Smriti
    Dodick, David W.
    Goadsby, Peter J.
    Zhang, Qi
    Ferguson, Margaret B.
    Oakes, Tina M.
    Martinez, James M.
    Due, Michael R.
    Schacht, Aaron L.
    Skljarevski, Vladimir
    Johnson, Kirk W.
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S381 - S382
  • [10] Safety, Pharmacokinetics, and Pharmacodynamics of LY2951742: A Monoclonal Antibody Targeting CGRP
    de Hoon, J.
    Montieth, D.
    Vermeersch, S.
    Van Hecken, A.
    Abu-Raddad, E.
    Collins, E.
    Schuetz, T.
    Scherer, J.
    Grayzel, D.
    CEPHALALGIA, 2013, 33 (S8) : 247 - 248
12345